Preclinical studies have supported the possible therapeutic targeting of CD123 in some hematologic malignancies, such as AMLs and blastic plasmocytoid dendritic neoplasms (BPDCNs) overexpressing this membrane receptor. The gene discussed is IL3RA; the disease is hematologic disorder.